Helmut H. Kessmann
Founder bij T3 Pharmaceuticals AG
Profiel
Helmut H.
Kessmann is the founder of Discovery Technologies Ltd (1996) and T3 Pharmaceuticals AG (2015), where he holds the title of Director.
He is currently a Director at Swiss Healthcare Licensing Group (since 2018).
Dr. Kessmann's former positions include Principal at Ciba-Geigy AG, Chief Business Officer at Graffinity Pharmaceuticals AG, Chief Business Officer at Santhera Pharmaceuticals Holding AG (2010-2011), and Head-Business Development at Spexis Ltd.
(2011-2019).
Dr. Kessmann received a doctorate degree from the University of Münster in 1988.
Actieve functies van Helmut H. Kessmann
| Bedrijven | Functie | Begin |
|---|---|---|
T3 Pharmaceuticals AG
 T3 Pharmaceuticals AG BiotechnologyHealth Technology T3 Pharmaceuticals AG provides medicines and treatment for cancer patient. The company was founded in May 2015 by Simon J. Ittig, Christoph A. Kasper, Marlise Amstutz and Helmut H. Kessmann and is headquartered in Basel, Switzerland. | Founder | 01-05-2015 |
| Swiss Healthcare Licensing Group | Director/Board Member | 01-02-2018 |
Eerdere bekende functies van Helmut H. Kessmann
| Bedrijven | Functie | Einde |
|---|---|---|
| SPEXIS AG | Corporate Officer/Principal | 01-12-2019 |
| SANTHERA PHARMACEUTICALS HOLDING AG | Corporate Officer/Principal | 31-10-2011 |
Ciba-Geigy AG
 Ciba-Geigy AG Pharmaceuticals: MajorHealth Technology Ciba-Geigy AG was manufacturing pharmaceuticals. The company was merged with Sandoz Ltd. to create Novartis AG. The company was founded in 1884 and was headquartered in Basle, Switzerland. | Corporate Officer/Principal | - |
Graffinity Pharmaceuticals AG
 Graffinity Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Graffinity Pharmaceuticals AG specializes in chemical genomics pharmaceutical products. Through its fragment based chemical genomics platform, it provides novel small molecules for drug discovery and chemical genomics approaches. The company was founded in 1998 and is headquartered in Heidelberg, Germany. | Corporate Officer/Principal | - |
Discovery Technologies Ltd
 Discovery Technologies Ltd Miscellaneous Commercial ServicesCommercial Services Part of Infinity Pharmaceuticals, Inc., Discovery Technologies Ltd is a Swiss company that provides high output screening capabilities, customized assay development/optimization, and chemical libraries. The private company is based in Basel, Switzerland. The company was founded by Helmut H. Kessmann. Discovery Technologies was acquired by Discovery Partners International, Inc. on December 31, 2000 for $7.20 million. | Founder | - |
Opleiding van Helmut H. Kessmann
| University of Münster | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| SANTHERA PHARMACEUTICALS HOLDING AG | Health Technology |
| SPEXIS AG | Health Technology |
| Bedrijven in privébezit | 5 |
|---|---|
Ciba-Geigy AG
Ciba-Geigy AG Pharmaceuticals: MajorHealth Technology Ciba-Geigy AG was manufacturing pharmaceuticals. The company was merged with Sandoz Ltd. to create Novartis AG. The company was founded in 1884 and was headquartered in Basle, Switzerland. | Health Technology |
Discovery Technologies Ltd
Discovery Technologies Ltd Miscellaneous Commercial ServicesCommercial Services Part of Infinity Pharmaceuticals, Inc., Discovery Technologies Ltd is a Swiss company that provides high output screening capabilities, customized assay development/optimization, and chemical libraries. The private company is based in Basel, Switzerland. The company was founded by Helmut H. Kessmann. Discovery Technologies was acquired by Discovery Partners International, Inc. on December 31, 2000 for $7.20 million. | Commercial Services |
Graffinity Pharmaceuticals AG
Graffinity Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Graffinity Pharmaceuticals AG specializes in chemical genomics pharmaceutical products. Through its fragment based chemical genomics platform, it provides novel small molecules for drug discovery and chemical genomics approaches. The company was founded in 1998 and is headquartered in Heidelberg, Germany. | Health Technology |
| Swiss Healthcare Licensing Group | |
T3 Pharmaceuticals AG
T3 Pharmaceuticals AG BiotechnologyHealth Technology T3 Pharmaceuticals AG provides medicines and treatment for cancer patient. The company was founded in May 2015 by Simon J. Ittig, Christoph A. Kasper, Marlise Amstutz and Helmut H. Kessmann and is headquartered in Basel, Switzerland. | Health Technology |
